文献速递肝病

一种不依赖纤维化的肝脏转录组特征可识别原发性硬化性胆管炎疾病进展的驱动因素

A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
PubMed 文献 · Hepatology · 2021-02-28

本研究对96周临床试验中74例原发性硬化性胆管炎(PSC)患者的肝组织进行RNA测序,用计算方法扣除纤维化影响后,鉴定出与临床事件相关的生物学通路;纤维化校正后的无监督聚类分出两个风险不同的患者群,高风险组临床事件明显更多(38% vs 2.4%,P<0.0001)。

要点

  • 纤维化校正后仍可区分出两个PSC患者群,其首次PSC相关事件风险差异显著(P<0.0001)。
  • 两群纤维化分期、肝胶原含量、α-SMA表达、ELF评分及血清指标均无显著差异(均P>0.05)。
  • 高风险群未折叠蛋白反应相关基因ATF6和eIF2表达下调(log倍数变化分别为-0.18和-0.16,均P=0.02)。

核心结论

  • 去除纤维化相关通路的影响后,未折叠蛋白反应的改变与PSC患者肝脏相关并发症相关。

研究设计与样本

  • 对入组96周临床试验的74例PSC患者肝组织行RNA测序,用计算方法扣除纤维化对基因表达的影响,分析纤维化校正后表达模式与首次PSC相关临床事件时间的关联。

主要发现

  • 基线中位年龄48岁,71%为男性,49%合并炎症性肠病,44%有桥接纤维化或肝硬化。
  • RNA测序数据第一主成分(PC1)解释18%的方差,与纤维化分期相关(ρ=-0.80;P<0.001)。
  • 去除纤维化相关基因影响后,第一主成分与纤维化无关(ρ=-0.19;P=0.11),半监督聚类识别出两个首次PSC相关事件时间风险不同的患者群(P<0.0001)。
  • 两群纤维化分期、形态计量肝胶原含量和α-平滑肌肌动蛋白表达、增强肝纤维化(ELF)评分及血清肝生化、胆汁酸、IL-8均相似(均P>0.05)。
  • 高风险群与低风险群相比临床事件更富集:38%(12/32)vs 2.4%(1/42),P<0.0001。

关键数值与推荐

  • Ingenuity通路分析排名靠前的通路为真核翻译起始因子2(eIF2)信号和eIF4/p70S6K信号调控。
  • 未折叠蛋白反应相关基因ATF6和eIF2在两个PSC聚类间差异表达,在高风险群中下调(log倍数变化分别为-0.18[P=0.02]和-0.16[P=0.02])。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a heterogeneous cholangiopathy characterized by progressive biliary fibrosis. RNA sequencing of liver tissue from patients with PSC (n = 74) enrolled in a 96-week clinical trial was performed to identify associations between biological pathways that were independent of fibrosis and clinical events. APPROACH AND RESULTS: The effect of fibrosis was subtracted from gene expression using a computational approach. The fibrosis-adjusted gene expression patterns were associated with time to first PSC-related clinical event (e.g., cholangitis, hepatic decompensation), and differential expression based on risk groups and Ingenuity Pathway Analysis were performed. Baseline demographic data were representative of PSC: median age 48 years, 71% male, 49% with inflammatory bowel disease, and 44% with bridging fibrosis or cirrhosis. The first principle component (PC1) of RNA-sequencing data accounted for 18% of variance and correlated with fibrosis stage (ρ = -0.80; P < 0.001). After removing the effect of fibrosis-related genes, the first principle component was not associated with fibrosis (ρ = -0.19; P = 0.11), and a semisupervised clustering approach identified two distinct patient clusters with differential risk of time to first PSC-related event (P < 0.0001). The two groups had similar fibrosis stage, hepatic collagen content, and α-smooth muscle actin expression by morphometry, Enhanced Liver Fibrosis score, and serum liver biochemistry, bile acids, and IL-8 (all P > 0.05). The top pathways identified by Ingenuity Pathway Analysis were eukaryotic translation inhibition factor 2 (eIF2) signaling and regulation of eIF4/p70S6K signaling. Genes involved in the unfolded protein response, activating transcription factor 6 (ATF6) and eIF2, were differentially expressed between the PSC clusters (down-regulated in the high-risk group by log-fold changes of -0.18 [P = 0.02] and -0.16 [P = 0.02], respectively). Clinical events were enriched in the high-risk versus low-risk group (38% [12/32] vs. 2.4% [1/42], P < 0.0001). CONCLUSIONS: Removing the contribution of fibrosis-related pathways uncovered alterations in the unfolded protein response, which were associated with liver-related complications in PSC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gindin Y, Chung C, Jiang Z, et al. A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. Hepatology. 2021. PMID: 32745270. doi:10.1002/hep.31488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。